The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from ...

The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia.

Moderna has withdrawn the Biologics License Application (BLA) for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after ...

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

Jivi is not indicated for use in patients less than 7 years old due to a greater risk for hypersensitivity reactions and/or loss of efficacy. The Food and Drug Administration (FDA) has expanded ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.